170725 Studienprotokolle Therapie laeuft

klinischen Studie der
Onkologie am Rotkreuzklinikum
Durchführung
GeparOcto
EudraCT Number
2014-000619-14
A randomized phase III trial comparing two dose-dense, dose-intensified
approaches (ETC and PM(Cb)) for neoadjuvant treatment of high-risk early
breast cancer (GeparOcto)
x
x
Onkologische Tagesklinik, Taxisstr. 3
und
Onkologische Schwerpunktpraxis Prof.
Dr. C. Salat u. Dr. O. J. Stötzer
Katherine BO27938
KATHERINE BO27938/B-51-I/ GBG77Studie zur Beurteilung der
Wirksamkeit und Sicherheit von Trastuzumab Emtansin im Vergleich zu
Herceptin ® als adjuvante Therapie bei Patienten mit HER2-positivem
primären Brustkrebs und pathologischem Resttumor in Brust oder axillären
Lymphknoten nach präoperativer Therapie
x
x
Onkologische Schwerpunktpraxis Prof.
Dr. C. Salat u. Dr. O. J. Stötzer
PRESENT
EutraCT number
2011-005219-98
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast
Cancer with Low to Intermediate HER2 Expression with NeuVax TM
Treatment. Phase III
x
TRIO-022
A5481008
EutraCT number
2012-004601-27
A randomized, multicenter, double-blind Phase 3 study of PD-0332991
(Oral CDK 4/6 inhibitor) plus letrozole versus placebo plus letrozole for
the treatment of postmenopausal women with ER (+), HER2 (-) breast
cancer who have not received any prior systemic anti-cancer treatment for
advanced disease.
x
Mamma-Ca
Mamma-Ca
Mamma-Ca
26.07.2016
x
x
x
Therapie läuft
TNBC
x
ER-HER2+
Mamma-Ca
Vollständiger Titel
ER+HER2+
A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study
Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin
Versus the Addition of Carboplatin to Standard Neoadjuvant
Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects
with Early Stage Triple Negative Breast Cancer (TNBC)
Kurztitel
ER+HER2-
Abbvie (Brightness)
GBG 81
EudraCT Number
2013-002377-21
Paliativ
x
Preventiv
Mamma-Ca
Adjuvant
Indikation
Neo-Adjuvant
Onkologische Tagesklinik, Taxisstr. 3
oder
Onkologische Schwerpunktpraxis
Prof. Dr. C. Salat u. Dr. O. J. Stötzer
x
x
Onkologische Tagesklinik, Taxisstr. 3
und
Onkologische Schwerpunktpraxis Prof.
Dr. C. Salat u. Dr. O. J. Stötzer
Onkologische Tagesklinik, Taxisstr. 3
Onkologische Tagesklinik, Taxisstr. 3
klinischen Studie der
Onkologie am Rotkreuzklinikum
Mamma-Ca
x
Mamma-Ca
x
BO25430
EutraCT number
2010-021067-32
Monaleesa3
CLEE011F2301
EudraCT Number
2015-00617-43
26.07.2016
x
AN OPEN-LABEL, MULTICENTER EXTENSION STUDY OF
TRASTUZUMAB EMTANSINE (TDM4529g) ADMINISTERED
AS A SINGLE AGENT OR IN COMBINATION WITH OTHER
ANTI-CANCER THERAPIES IN PATIENTS PREVIOUSLY
ENROLLED IN A GENENTECH AND /OR
F. HOFFMANN-LA ROCHE LTD–SPONSORED
TRASTUZUMAB EMTANSINE STUDY
A randomized double-blind, placebo-controlled study of LEE011 (CDK4/6
inhibitor) in combination with fulvestrant for the treatment of men and
postmenopausal women with hormone receptor positive, HER2-negative,
advanced breast cancer who have received no or only one line of prior
endocrine treatment
Therapie läuft
x
x
Onkologische Tagesklinik, Taxisstr. 3
Onkologische Tagesklinik, Taxisstr. 3
und
Onkologische Schwerpunktpraxis Prof.
Dr. C. Salat u. Dr. O. J. Stötzer

Download Report